Mucinex® for Treatment of Filamentary Keratitis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Change in Number of Corneal Filaments
研究概览
简要总结
It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.
详细描述
The study is aimed to determine if oral administration of Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis. Subjects will be instructed to take 600 mg tablets of extended release Mucinex® twice a day (total dose is 1.2 g/day) for 4 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with filamentary keratitis
- •18 years and older
排除标准
- •Active ocular surface infection of any type
- •Recent ocular surgery (<30 days) history of nephrolithiasis as Mucinex® has been associated in rare cases of development of kidney stones
- •Schirmer's test<3mm
- •History of hypersensitivity to Mucinex®
- •Concurrent eye disease requiring immediate initiation of a new treatment (e.g. topical steroids) restriction for water intake can exacerbate the risk of nephrolithiasis.
研究组 & 干预措施
Mucinex
600 mg of Mucinex 2 times a day.
干预措施: Mucinex® (Drug)
结局指标
主要结局
Change in Number of Corneal Filaments
时间窗: baseline (day 1) and week 4
Change was calculated as the value after receiving treatment with guaifenesin for 4 weeks minus the value at baseline.
次要结局
- Change in OSDI Score(baseline (day 1) and week 4)
研究者
Reza Dana, MD
Reza Dana, MD, MPH, MSc
Massachusetts Eye and Ear Infirmary